Satraplatin demonstrates clinical benefit in patients with advanced hormone-refractory prostate cancer: Results of the global phase III satraplatin and prednisone against refractory cancer (sparc) trial

被引：0
|
作者：
Sartor, O.
Petrylak, D.
Witjes, F.
Berry, W.
Chatta, G.
Vaughn, D.
Sternberg, C. N.
机构：
来源：
CANCER INVESTIGATION | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 20
页数：2
相关论文
共 50 条
  • [1] Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial
    Sartor, A. O.
    Petrylak, D. P.
    Witjes, J. A.
    Berry, W. R.
    Chatta, G. S.
    Vaughn, D. J.
    Ferrero, J.
    Demkow, T.
    Eymard, J. C.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Satraplatin for hormone-refractory prostate cancer
    Kerr, Cathel
    LANCET ONCOLOGY, 2007, 8 (04): : 290 - 290
  • [3] Satraplatin in the treatment of hormone-refractory prostate cancer
    Sternberg, CN
    BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
  • [4] Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
    Sternberg, CN
    Whelan, P
    Hetherington, J
    Paluchowska, B
    Slee, PHTJ
    Vekemans, K
    Van Erps, P
    Theodore, C
    Koriakine, O
    Oliver, T
    Lebwohl, D
    Debois, M
    Zurlo, A
    Collette, L
    ONCOLOGY, 2005, 68 (01) : 2 - 9
  • [5] Pain and psa responses in metastatic hormone refractory prostate cancer treated with satraplatin: Results of the SPARC phase III trial
    Witjes, J. A.
    Petrylak, D.
    Sartor, O.
    Demkow, T.
    Ferrero, J. M.
    Eymard, J. C.
    Falcon, S.
    Karyakine, O. B.
    Kneter, O.
    Sternberg, C.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 100 - 100
  • [6] Satraplatin significantly improves progression free survival (PFS) and pain control in patients with advanced hormone-refractory prostate cancer (HRPC): Preliminary results from the phase III sparc trial
    Sartor, Oliver
    Sternberg, Cora
    Witjes, J. Alfred
    Chatta, Gurkamal
    Vaughn, David
    Berry, William
    Lara, Primo, Jr.
    Nathan, Faith E.
    McKeam, Tom
    Petrylak, Daniel P.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 335 - 335
  • [7] Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour TypesPharmacological Properties and Clinical Evaluation
    Mark J. McKeage
    Drugs, 2007, 67 : 859 - 869
  • [8] Satraplatin in hormone-refractory prostate cancer and other tumour types - Pharmacological properties and clinical evaluation
    McKeage, Mark J.
    DRUGS, 2007, 67 (06) : 859 - 869
  • [9] Satraplatin in the treatment of hormone-refractory prostate cancer (vol 96, pg 990, 2005)
    Sternberg, CN
    BJU INTERNATIONAL, 2006, 97 (01) : 211 - 211
  • [10] Satraplatin: A new treatment option for patients with hormone refractory prostate cancer.
    Nathan, FE
    Sternberg, C
    Sartor, O
    Petrylak, D
    Witjes, F
    Wosikowski, K
    Petrone, ME
    Rozencweig, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 453S - 453S
12345